Guidelines for the use of unlicensed and off label medication within NHS Fife Addiction Services
|
|
- Lynette McLaughlin
- 8 years ago
- Views:
Transcription
1 NHS Fife Community Health Partnerships Addiction Services Guidelines for the use of unlicensed and off label medication within NHS Fife Addiction Services Intranet Procedure No. A11 Author Dr A. Baldacchino Copy No 1 Reviewer Lead Clinician Implementation Date April 2011 Status Authorised 2011 Last Review Date Approved By Medical Director Primary Care Next Review Date April 2013 Head of Nursing NHS Fife 1 Function 1.1 To ensure safe and effective prescribing of unlicensed and off-label medicaton to patients being treated for substance misuse. 2 Location 2.1 NHS Fife out-patient and in-patient services 3 Responsibility 3.1 Prescribing of unlicensed medication is restricted to Consultant Psychiatrists and is to be in accordance with NHS Fife Policy for the use of Unlicensed Medicines. 3.2 Medical and non medical prescribers in Fife NHS Addiction Service may prescribe off-label medication in accordance with NHS Fife Policy for the use of unlicensed medicines 4 Operational System 4.1 In addition to those indications where the use of off-label medication has become accepted practice, the use of unlicensed and off-label medication is a treatment option for: Patients who have failed to respond to licensed medication. Patients who have had a partial response to licensed medication, but a trial of a higher than the maximum licensed dose is considered appropriate. Page 1 of 9
2 4.2 It is essential that all patients give informed consent to off-label prescribing. This should be clearly documented in the clinical records. Where available, patients should be given a patient information leaflet prior to off-label prescribing. (See example Appendix 1) 4.3 The following medications may be initiated and continued without Consultant Psychiatrist authorisation: Diazepam only for detoxification in benzodiazepine dependence. Naltrexone for use as an adjunct to maintaining abstinence in alcohol misuse disorders. Acamprosate for use during alcohol detoxification for patients who have had frequent detoxification from alcohol. Suboxone up to 32mg daily when used in accordance to the relevant NHS Fife guidance document on buprenorphine titration. Guidance on off-label use of these drugs is given below. 4.4 All other off-label prescribing must be authorised by a Consultant Psychiatrist and supported by a Prescribing Review plan with medical review date clearly stated. Treatments that have accepted off-label for treatment of substance misuse within NHS Fife Addiction Services are: Baclofen for use in alcohol dependence Diazepam in benzodiazepine dependence 4.5 Communication with GP: Prior to transferring the prescribing to a patient s GP, a letter explaining the rationale for offlabel prescribing in that case should be sent. A copy of the prescribing review sheet should also be enclosed. If the GP is willing to take on prescribing, a date for transfer of prescribing should be agreed. 5 Diazepam for use in benzodiazepine withdrawal 5.1 Diazepam may be prescribed as a medically supported detoxification regimen using the appropriate NHS Fife guidance document. Regimens outside this document must be authorised by the prescribing doctor. Slower detoxification courses must only be considered if one of the following apply: Deterioration in mental health resulting in undue distress and increased risk of self harm. Unacceptable objective alcohol withdrawal symptoms. Iatrogenic dependence greater that three years in which case suggested length of detoxification is one month per year of iatrogenic dependence, up to a maximum of twelve months duration of treatment. 5.2 Patients who require stabilisation of diazepam for more than three months should be referred to senior medical staff for assessment. 6 Naltrexone as an adjunct in relapse prevention for alcohol dependence 6.1 Naltrexone hydrochloride tablets are licensed as an adjunct in relapse prevention of detoxified opioid dependent patients (who have remained opiate free for at least 7 10 days). 6.2 Naltrexone is not licensed for the treatment of alcohol dependence in the UK. Page 2 of 9
3 6.3 Naltrexone is a long acting opioid antagonist and is given in tablet form. If taken on a regular basis after detoxification from alcohol, it can assist in relapse prevention as an adjunct to psychosocial intervention. 6.4 Several studies on naltrexone found this opioid antagonist to be more effective than placebo in reducing relapse rates, increasing the percentage of non drinking days and reducing craving for alcohol in heavy drinkers; however, some other studies failed to demonstrate a significant difference from placebo. 6.5 Due to its scarce evidence this treatment should only be considered if disulfiram and acamprosate have not been successful or are contra-indicated. 6.6 Naltrexone is extensively metabolised by the liver and excreted predominately in the urine. It should be used with caution in patients with impaired hepatic and/or renal function. Liver function tests (LFTs) should be monitored before commencing treatment, and at one and six month intervals. According to this, treatment with naltrexone should be discontinued if there is evidence of progressive hepatic impairment. Arrangements for LFT monitoring should be made available regularly for patients prior to commencing treatment as well as for its entire duration. This pre-treatment monitoring will determine the suitability of patients for this medication and will also establish a baseline for comparison with future tests. 6.7 Treatment plans for patients who are under medical care for liver disease should be discussed with the responsible physician prior to initiating treatment. 6.8 Naltrexone is contraindicated in patients: With acute hepatitis or liver failure Currently dependant on opioids or taking an opioid-containing medication 6.9 The patient should be given a caution card as issued by the drug manufacturer Dosing regime: The initial dose should be 25mg (half a tablet) followed by 50mg daily. The total weekly dose may be divided and be given 3 times a week to improve compliance. For example, 100mg on Mondays and Wednesdays and 150mg on Fridays Success of treatment should be assessed by using alcohol diary, Audit and SADQ. These must be completed prior to commencement of treatment. A lack of significant improvement in both of these measures after three months of treatment will lead to discontinuation If there is evidence of clinical benefit, naltrexone prescribing should continue for at least 6 12 months. 7 Acamprosate for use during Alcohol Detoxification Page 3 of 9
4 7.1 A number of studies have evidenced that acamprosate may protect against neurotoxicity under the conditions of high polyamine activation that occurs during alcohol withdrawal, which possibly contributes to neuronal loss occasionally seen in chronic alcohol dependence. 7.2 Acamprosate administered during withdrawal states does not appear to cause any unwanted effects. 7.3 In alcohol dependent patients exposed to repeated detoxifications from alcohol, the use of acamprosate during detoxification for neuroprotection may be warranted and should be discussed with senior medical staff. The adequate dose should then be prescribed; four or six 333mg tablets daily (dependent upon weight) in divided doses. The continued use post detoxification should be assessed depending on treatment needs. 8 Suboxone up to 32mg daily 8.1 Where a patient has been commenced on Suboxone and has not stabilised on a dose of 24mg, a trial period of one month on 32mg may be warranted: If the patient fails to stabilise on 32mg then titration onto methadone should be considered. If the patient stabilises on 32mg then switching to buprenorphine alone should be considered. Prolonged use of doses above 24mg must be authorised at consultant level. 9 Baclofen for use in alcohol dependence 9.1 Baclofen has been shown to reduce alcohol craving and intake, and enhance abstinence in alcohol-dependent patients. 9.2 Baclofen has low liver metabolism (about 15%) and is mainly eliminated unmodified by the kidneys, and can therefore be used in individuals affected by liver cirrhosis for whom licensed medication is contraindicated. 9.3 Clinical trials have shown baclofen to reduce anxiety levels in patients with alcohol related difficulties. 9.4 Inclusion Criteria For maintenance of abstinence after detoxification in alcohol-dependent patients: Where licensed medications acamprosate and disulfiram are contraindicated or not tolerated. Who have relapsed on previous attempts using psychosocial treatment and licensed medication. Who have previously relapsed due to severe anxiety symptoms 9.5 Exclusion Criteria Under 16 years of age Unable to give informed consent 9.6 Baclofen is contraindicated in patients with peptic ulceration Page 4 of 9
5 9.7 Patients should receive the patient information leaflet (Appendix 1) and sign a treatment contract prior to commencement of treatment. 9.8 Dosage regime Side effects are more likely to occur if a very high a dose is initiated or if the dose is increased very rapidly. Recommended initial dose of 5mg three times daily for three days Increasing the dose to 10mg three times a day if side effects are minimal. Further titration by increments of 5mg three times daily every three days can be arranged in response to continued craving and monitored side effects. Doses of up to 100mg per day may be required however doses above 100mg should be authorised by the Consultant. 9.9 Monitoring Response to baclofen will be monitored using the SADQ, Audit, alcohol diaries, alcohol craving questionnaire, liver function tests and Mean Corpuscular Volume (MCV). These will be completed prior to commencing treatment and monthly for the first three months. In clinical practice if there is no positive effect after one month on maximum dose baclofen, treatment will be discontinued. If a therapeutic trial shows a good response, there will be a review within six months and a total duration of treatment up to one year may be suggested. Relapse after cessation of treatment may warrant further treatment. Side effects from medication are dose related and should be recorded at each patient review Special warnings and precautions Baclofen stimulates gastric acid secretion and should be used with caution in patients with a history of peptic ulcer and avoided in those with active peptic ulcer disease Use with caution in patients with severe psychiatric disorders or epilepsy or convulsive disorders as these disorders may be exacerbated by baclofen. Slower titration and weekly monitoring during titration must be implemented in this patient group As baclofen is excreted mainly unchanged by the kidneys, patients with renal impairment will only tolerate lower doses Liver function should be monitored in patients with liver disease Use with caution in patients with: Respiratory impairment Diabetes mellitus Cerebrovascular diseases Baclofen may cause drowsiness; patients affected should not drive or operate machinery. Page 5 of 9
6 Abrupt withdrawal. Serious side effects can occur on abrupt withdrawal of baclofen; to minimise risk, it is recommended discontinuation by gradual dose reduction over at least 1-2 weeks (longer if symptoms occur) Interactions Concomitant treatment with antihypertensive medication is likely to enhance the hypotensive effect. Blood pressure must be monitored weekly during titration and dose of antihypertensive adjusted accordingly. The muscle relaxant effect of baclofen may be enhanced by tricyclic antidepressants. Ibuprofen and other drugs that produce renal insufficiency may reduce baclofen excretion leading to toxicity. Increased sedation may occur if taken with medications acting on the CNS (for example: opioids and alcohol). Baclofen will be prescribed for patients to promote total abstinence from alcohol and will not be continued in patients who resume drinking. 10 References Policy for the use of Unlicensed Medicines. NHS Fife BNF current edition. Section 4.1 Hypnotics and anxiolytics: Dependence amd withdrawal. Lingford-Hughes, A., Welch, S., Nutt, D., Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychpharmacology. Journal of Psychpharmacology 18(3) 2004, Koob, G., Mason, B., De Witte, P., et al Potential Neuroprotective Effects of Acamprosate. Alcoholism: Clinical and Experimental Research. Vol. 26, No. 4, April 2002: pp Gual, A., and Lehert, P., Acamprosate during and after acute alcohol withdrawal: adouble blind placebo-controlled study in Spain. Alcohol & Alcoholism, Vol. 36, No. 5, 2001, pp Slattery, J., Chick, J., Cochrane, M., et al Prevention of relapse in alcohol dependence Health Technology Assessment report 3. Health Technology Board of Scotland, December Addolorato, G., Leggio, L., Ferruli, A., et al. Effectiveness and safety of baclofen for maitenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis:randomised, double-blind controlled study. The Lancet 370, 2007; Page 6 of 9
7 Appendix 1 Information leaflet for Baclofen NHS Fife Addiction Services PATIENT INFORMATION LEAFLET BACLOFEN IN THE TREATMENT OF ALCOHOL DEPENDENCE Three published studies from Italy have suggested that Baclofen reduces the relapse rate in patients with a drinking problem who are trying to abstain from alcohol. It also appears to reduce the sense of craving for alcohol that some patients experience. It has been used safely in patients who have liver damage due to alcohol. It is not yet licensed for alcohol related disorders in the UK. It has been licensed as a muscle relaxant for some 30 years and is widely used in multiple sclerosis, after strokes, sometimes after spinal injury such as slipped disc to relieve spasms, cramping, and tightness of muscles. Baclofen does not cure these problems, but it may allow other treatment, such as physical therapy, to be more helpful. SIDE EFFECTS Baclofen acts on the central nervous system (CNS) to produce its muscle relaxant effects. Its actions on the CNS may also cause some of the medicine's side effects: drowsiness, dizziness, vision problems, or clumsiness or unsteadiness, or a feeling of muscle weakness. A rare side effect has been to increase the possibility that someone will have a seizure. One patient had temporary bladder weakness with incontinence, which ceased when the dose was reduced. As with most medicines which act on the CNS, such as antidepressants, tranquillisers, sleeping tablets, or anticonvulsants, we advise: Know how you react to this medicine before you drive, or use machines. What if I drink alcohol after taking Baclofen? The clumsiness or unsteadiness would be more likely if alcohol was consumed on a day when the person had taken a Baclofen tablet. Do not drink alcohol with the tablets. Baclofen is prescribed to help abstinence from alcohol. If you do take a drink, try and put the brakes on immediately, and resume taking the Baclofen. Does Baclofen interact with my other medication? There are possible interactions with medications used to treat high blood pressure or certain analgesics and a few other medicines. These are listed in the Patient information Leaflet issued by the manufacturer. If you are taking the older tricyclic antidepressants, such as amitriptyline or Imipramine, with Baclofen it may cause unsteadiness or a feeling of muscle weakness. Please advise your doctor of all other medications you take. Page 7 of 9
8 Is Baclofen addictive? It is not known to be abused, or addictive. There have been a few cases where an individual increased the dose beyond the prescribed dose. Withdrawal symptoms have been described in the days following a large overdose, however we recommend that Baclofen should not be stopped suddenly, rather, gradual decrease over a few days is recommended What dose is prescribed? The usual starting dose is 5mg three times per day increasing gradually to 10 mg three times daily, but your doctor may advise gradual increase to a higher dose, up to a maximum of 100 mg in one day. What can I expect when I start Baclofen? In the beginning of the treatment you might have to be patient. Everybody is different and will need a different dose to decrease and stop craving and symptoms of alcoholism. To avoid side effects (mainly tiredness); we have to increase the dose slowly (typically every 3 days). If you feel craving or you get in a particularly difficult situation it might be good for you to take an extra dose (usually half your normal dose is all that is needed). You should not increase by more than two tablets per day without discussion with the prescribing doctor. If there is no positive effect seen after 1 month, Baclofen treatment will usually be discontinued. The aim is to find a dosing schedule (number and timing of tablets) of Baclofen with which you do not have any craving or thoughts of alcohol. We would expect your body to get used to the dose and not feel tired with this schedule. In situations which have caused cravings in the past (such as passing by the off licence you regularly went to, a party, an anniversary, passing or going to a pub) you might still feel some craving if you don t take an extra dose of Baclofen. It is therefore good to always have some Baclofen with you and take a dose in these situations as soon as possible. Be aware that it takes some time (from about half an hour to about 3 hours) to work. If you do take an additional dose, be extra careful because of the sleepiness it may cause. Driving in these situations is certainly dangerous! I also smoke or have other addiction and psychiatric problems. Does the treatment deal with all of them at once? Baclofen may help you get off these addictive substances, but it might be best concentrate on one addiction at a time. It is important though to not replace one addiction with another. In your case you and your doctor have come to the conclusion that the alcohol problem is most damaging for your body and should be tackled at the moment. Some people notice a benefit on their anxiety or mood levels. This obviously helps with staying off the alcohol. How do I stop baclofen? If a therapeutic trial shows a good response, there will be a review at 6 months, and a total duration of up to one year may be suggested. The body gets used to baclofen (but not addicted). Therefore baclofen must not be stopped suddenly and your doctor will reduce the dose before stopping it. What if I still have strong craving or drink despite taking the baclofen? If you have strong thoughts and urges to drink, of if you lapse and drink alcohol, this may mean that you need a higher dose of baclofen. Speak to your doctor to decide whether to increase your regular doses or whether to take extra doses in certain situations (or both). Page 8 of 9
9 Why have I not been given baclofen before? Baclofen is a drug we have a lot of experience with in different patients, but it was only relatively recently considered to be potentially helpful in addictions including alcoholism. Is it a magic bullet? No! It helps you to overcome the craving and thoughts about alcohol. It does not work if you are not motivated to reduce and stop drinking. Remember why you decided to do something about your drinking! What else do I need to do? Alcohol causes damage to your body; your alcohol consumption therefore has to change and from the assessment, your doctor knows that you are able to overcome the addiction. Therefore you are already closer to abstinence and a healthier life than many other people. When you take the medication you need to work together with your doctor to help you. This means telling your doctor when you had problems taking the medication or when you found it difficult to stay off the alcohol as soon as possible. Everybody in your situation has tried stopping drinking alcohol, but for one reason or another, started drinking again (relapsed). To be able to stop relapses from happening it is important to find out for yourself in which situations you are most likely to relapse. In the beginning you will certainly need to avoid these difficult situations which might start you on the alcohol again. Also, always have some baclofen with you just in case. Have activities and relationships that you enjoy and that do not involve alcohol. You can discuss with your doctor, the hospital alcohol nurse and your GP which help is available (e.g. Community alcohol team, self help groups such as AA) and what would suit you. They can put you in touch with the help you need. Further information NHS Fife Addiction Service Page 9 of 9
Adjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.
Shared Care Guideline for Prescription and monitoring of Naltrexone Hydrochloride in alcohol dependence Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist,
More informationNaltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance
Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance Introduction Indication/Licensing information: Naltrexone is licensed for use as an additional therapy, within
More informationMaintenance of abstinence in alcohol dependence
Shared Care Guideline for Prescription and monitoring of Acamprosate Calcium Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist, Alcohol Services Dr Donnelly
More informationHow To Use Naltrexone Safely And Effectively
Naltrexone And Alcoholism Treatment Treatment Improvement Protocol (TIP) Series 28 Executive Summary and Recommendations Psychosocial treatments for alcoholism have been shown to increase abstinence rates
More informationSPECIFICATION FOR THE LOCAL COMMISSIONED SERVICE FOR THE MANAGEMENT ALCOHOL MISUSE
SPECIFICATION FOR THE LOCAL COMMISSIONED SERVICE FOR THE MANAGEMENT OF ALCOHOL MISUSE Date: March 2015 1 1. Introduction Alcohol misuse is a major public health problem in Camden with high rates of hospital
More informationNHS FORTH VALLEY. Guidance on Alcohol Dependence: Maintenance of Abstinence. Contact: Valerie Kippen Area Drug & Therapeutics Committee
NHS FORTH VALLEY Guidance on Alcohol Dependence: Maintenance of Abstinence Approved 06/09/2012 Version 5.0 Date of First Issue February 2008 Review Date 06/09/2014 Current Issue Date 26/11/2012 EQIA Yes
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PDP IBT Inj - Vivitrol Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Opiate Antagonist Client: 2007 PDP IBT Inj Approval Date: 2/20/2007
More informationCo-morbid physical disorders e.g. HIV, hepatitis C, diabetes, hypertension. Medical students will gain knowledge in
1.0 Introduction Medications are used in the treatment of drug, alcohol and nicotine dependence to manage withdrawal during detoxification, stabilisation and substitution as well as for relapse prevention,
More informationDrugs for Alcohol Dependence: Clinical Guidance and Three Way Agreement
Drugs for Alcohol Dependence: Clinical Guidance and Three Way Agreement for County Durham In partnership with the GP, the client, and the County Durham Drug and Alcohol Service December 2015 Version 1.0
More informationMOH CLINICAL PRACTICE GUIDELINES 2/2008 Prescribing of Benzodiazepines
MOH CLINICL PRCTICE GUIELINES 2/2008 Prescribing of Benzodiazepines College of Family Physicians, Singapore cademy of Medicine, Singapore Executive summary of recommendations etails of recommendations
More informationDRUG AND ALCOHOL DETOXIFICATION: A GUIDE TO OUR SERVICES
01736 850006 www.bosencefarm.co.uk DRUG AND ALCOHOL DETOXIFICATION: A GUIDE TO OUR SERVICES An environment for change Boswyns provides medically-led drug and alcohol assessment, detoxification and stabilisation.
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: CSD - Suboxone Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Analgesics and Antipyretics (Opiate Partial Agonists) Client: County of San
More informationPrescription Drug Abuse
Prescription Drug Abuse Introduction Most people take medicines only for the reasons their health care providers prescribe them. But millions of people around the world have used prescription drugs for
More informationMedication for the Treatment of Alcohol Use Disorder. Pocket Guide
Medication for the Treatment of Alcohol Use Disorder Pocket Guide Medications are underused in the treatment of alcohol use disorder. According to the National Survey on Drug Use and Health, of the estimated
More informationInformation for Pharmacists
Page 43 by 42 CFR part 2. A general authorization for the release of medical or other information is NOT sufficient for this purpose. Information for Pharmacists SUBOXONE (buprenorphine HCl/naloxone HCl
More informationGuidelines for the Prescribing, Supply and Administration of Methadone and Buprenorphine on Transfer of Care
Hull & East Riding Prescribing Committee Guidelines for the Prescribing, Supply and Administration of Methadone and Buprenorphine on Transfer of Care 1. BACKGROUND Patients who are physically dependent
More informationNon medical use of prescription medicines existing WHO advice
Non medical use of prescription medicines existing WHO advice Nicolas Clark Management of Substance Abuse Team WHO, Geneva Vienna, June 2010 clarkn@who.int Medical and Pharmaceutical role Recommendations
More informationBenzodiazepine & Z drugs withdrawal protocol
Benzodiazepine & Z drugs withdrawal protocol Rationale The NSF for Older People has highlighted the issues of dependence, sedation and fall in the elderly when taking these types of medications. It has
More informationGUIDELINES FOR COMMUNITY ALCOHOL DETOXIFICATION IN SHARED CARE
GUIDELINES FOR COMMUNITY ALCOHOL DETOXIFICATION IN SHARED CARE Dr Millicent Chikoore MBBS MRCPsych Dr O Lagundoye MBBS MRCPsych Community based alcohol detoxification is a safe and effective option for
More informationOpioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians
Opioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians Although prescription pain medications are intended to improve the lives of people with pain, their increased use and misuse
More informationThis controlled document shall not be copied in part or whole without the express permission of the author or the author s representative.
This document can be made available in large print and other formats and languages, upon request. Please call NHS Grampian Corporate Communications on 01224 551116 or 01224 552245. This controlled document
More informationThe Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office
The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office Adopted April 2013 for Consideration by State Medical Boards 2002 FSMB Model Guidelines
More informationMethadone treatment Information for service users Page
South London and Maudsley NHS Foundation Trust Methadone treatment Information for service users Page What can happen if I stop using heroin? If you are addicted to or dependent on heroin, you develop
More informationAlcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence
Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence Issued: February 2011 guidance.nice.org.uk/cg115 NICE has accredited the process used by the Centre
More informationLike cocaine, heroin is a drug that is illegal in some areas of the world. Heroin is highly addictive.
Heroin Introduction Heroin is a powerful drug that affects the brain. People who use it can form a strong addiction. Addiction is when a drug user can t stop taking a drug, even when he or she wants to.
More informationMedicines To Treat Alcohol Use Disorder A Review of the Research for Adults
Medicines To Treat Alcohol Use Disorder A Review of the Research for Adults Is This Information Right for Me? Yes, this information is right for you if: Your doctor* said you have alcohol use disorder
More informationShared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia
Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia Version: 3.0 Ratified by: Medicines Committee Date ratified: 16 th November 2011 Name of originator/author: James
More informationFrequently asked questions
Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction Frequently asked questions What is Naltrexone? Naltrexone is a prescription drug that completely blocks the effects of all opioid drugs
More informationAlcohol use disorders: sample chlordiazepoxide dosing regimens for use in managing alcohol withdrawal
Alcohol use disorders: sample chlordiazepoxide dosing regimens for use in managing alcohol withdrawal February 2010 NICE clinical guidelines 100 and 115 1 These sample chlordiazepoxide dosing regimens
More informationSubstance Abuse Treatment. Naltrexone for Extended-Release Injectable Suspension for Treatment of Alcohol Dependence
Spring 2007 Volume 6 Issue 1 ADVISORY News for the Treatment Field Naltrexone for Extended-Release Injectable Suspension for Treatment of Alcohol Dependence What is naltrexone for extendedrelease injectable
More informationReintegration. Recovery. Medication-Assisted Treatment for Alcohol Dependence. Reintegration. Resilience
Reintegration Recovery Medication-Assisted Treatment for Alcohol Dependence Reintegration Resilience 02 How do you free yourself from the stress and risks of alcohol dependence? Most people cannot do it
More informationNaltrexone and Alcoholism Treatment Test
Naltrexone and Alcoholism Treatment Test Following your reading of the course material found in TIP No. 28. Please read the following statements and indicate the correct answer on the answer sheet. A score
More informationMedical marijuana for pain and anxiety: A primer for methadone physicians. Meldon Kahan MD CPSO Methadone Prescribers Conference November 6, 2015
Medical marijuana for pain and anxiety: A primer for methadone physicians Meldon Kahan MD CPSO Methadone Prescribers Conference November 6, 2015 Conflict of interest statement No conflict of interest to
More informationOne example: Chapman and Huygens, 1988, British Journal of Addiction
This is a fact in the treatment of alcohol and drug abuse: Patients who do well in treatment do well in any treatment and patients who do badly in treatment do badly in any treatment. One example: Chapman
More informationOpioid Agonist Therapy: The Duration Dilemma Edwin A. Salsitz, MD, FASAM Mount Sinai Beth Israel, New York, NY March 10, 2015
Q: I have read 40 mg of methadone stops withdrawal, so why don t we start at 30mg and maybe later in the day add 10mg? A: Federal Regulations stipulate that 30mg is the maximum first dose in an Opioid
More informationMedications for chronic pain
Medications for chronic pain When it comes to treating chronic pain with medications, there are many to choose from. Different types of pain medications are used for different pain conditions. You may
More informationIntegrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings
Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings All-Ohio Conference 3/27/2015 Christina M. Delos Reyes, MD Medical Consultant,
More informationAlcohol-use disorders
Issue date: February 2011 Alcohol-use disorders Diagnosis, assessment and management of harmful drinking and alcohol dependence Alcohol dependence: NICE guideline FINAL DRAFT (February 2011) 1 NICE clinical
More informationElements for a public summary. VI.2.1 Overview of disease epidemiology. VI.2.2 Summary of treatment benefits
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Pain is one of the most common reasons for a patient to seek medical attention. Moderate or severe intensity pain can be acute
More informationTreatment and Interventions for Opioid Addictions: Challenges From the Medical Director s Perspective
Treatment and Interventions for Opioid Addictions: Challenges From the Medical Director s Perspective Dale K. Adair, MD Medical Director/Chief Psychiatric Officer OMHSAS 1 Treatment and Interventions for
More informationTreatment of Alcoholism
Treatment of Alcoholism Why is it important Prevents further to body by getting people off alcohol. Can prevent death. Helps keep health insurance down. Provides assistance so alcoholics don t t have to
More informationBenzodiazepine Detoxification and Reduction of Long term Use
Benzodiazepine Detoxification and Reduction of Long term Use Malcolm Lader 1 Model of general drug misuse and dependence. Tactical interventional options Social dimension Increasing breaking of social
More informationAlcohol-use disorders
Issue date: February 2011 Alcohol-use disorders Diagnosis, assessment and management of harmful drinking and alcohol dependence Alcohol dependence: NICE guideline FINAL DRAFT (February 2011) 1 NICE clinical
More informationTHE BASICS. Community Based Medically Assisted Alcohol Withdrawal. World Health Organisation 2011. The Issues 5/18/2011. RCGP Conference May 2011
RCGP Conference May 2011 Community Based Medically Assisted Alcohol Withdrawal THE BASICS An option for consideration World Health Organisation 2011 Alcohol is the world s third largest risk factor for
More informationAlcohol and Drug. A Cochrane Handbook. losief Abraha MD. Cristina Cusi MD. Regional Health Perugia
Alcohol and Drug A Cochrane Handbook losief Abraha MD Regional Health Perugia of Cristina Cusi MD Outpatient Services - Neurology Clinical Institutes of Specialisation Milan Italy A John Sons, Ltd., THE
More informationADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines - 2015
The Clinical Level of Care Guidelines contained on the following pages have been developed as a guide to assist care managers, physicians and providers in making medical necessity decisions about the least
More informationAugust 2011. A. Introduction
Recommendations of the Expert Group on the Regulatory Framework for products containing buprenorphine / naloxone and buprenorphine-only for the treatment of opioid dependence August 2011 A. Introduction
More informationRelapse prevention clinic
Relapse prevention clinic Doncaster drug and alcohol services RDaSH Substance Misuse Services Relapse Prevention Clinic Sinclair House 29-31 Thorne Road Doncaster DN1 2EZ Tel: 01302 303900 Treatment, support
More informationOpioid Treatment Services, Office-Based Opioid Treatment
Optum 1 By United Behavioral Health U.S. Behavioral Health Plan, California Doing Business as OptumHealth Behavioral Solutions of California ( OHBS-CA ) 2015 Level of Care Guidelines Opioid Treatment Services,
More informationNaltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction. Frequently Asked Questions
Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction Frequently Asked Questions What is Naltrexone? Naltrexone is a prescription drug that effectively blocks the effects of heroin, alcohol,
More informationAppendix to Tennessee Department of Health: Tennessee Clinical Practice Guidelines for Outpatient Management of Chronic Non- Malignant Pain
Appendix to Tennessee Department of Health: Tennessee Clinical Practice Guidelines for Outpatient Management of Chronic Non- Malignant Pain Division of Workers Compensation 04.01.2015 Background Opioids
More informationOxford Health NHS Foundation Trust. A guide to Opioid Detoxification
Oxford Health NHS Foundation Trust A guide to Opioid Detoxification If you re considering detox, congratulations. You have obviously been visualising a drug free life and planning your future goals. Detox
More informationCommunity and Home Detox - An overview of service provision
Community and Home Detox - An overview of service provision David Prentice Clinical Charge Nurse Community and Home Detox CADS Auckland Waitemata District Health Board Overview Medical Detox Services In-patient
More informationSCOTTISH PRISON SERVICE DRUG MISUSE AND DEPENDENCE OPERATIONAL GUIDANCE
SCOTTISH PRISON SERVICE DRUG MISUSE AND DEPENDENCE OPERATIONAL GUIDANCE 1 P a g e The following Operational Guidance Manual has been prepared with input from both community and prison addictions specialists
More informationOVERVIEW WHAT IS POLyDRUG USE? Different examples of polydrug use
Petrol, paint and other Polydrug inhalants use 237 11 Polydrug use Overview What is polydrug use? Reasons for polydrug use What are the harms of polydrug use? How to assess a person who uses several drugs
More informationAlcohol treatment Information for service users Page
South London and Maudsley NHS Foundation Trust Alcohol treatment Information for service users Page This leaflet tells you what you can expect during treatment for problems related to using alcohol. It's
More informationCocaine. Like heroin, cocaine is a drug that is illegal in some areas of the world. Cocaine is a commonly abused drug.
Cocaine Introduction Cocaine is a powerful drug that stimulates the brain. People who use it can form a strong addiction. Addiction is when a drug user can t stop taking a drug, even when he or she wants
More informationDEVELOPING MANUFACTURING SUPPLYING. Naltrexone Implants. Manufactured by NalPharm Ltd WWW.NALPHARM.COM
DEVELOPING MANUFACTURING SUPPLYING Naltrexone Implants Background to Nalpharm NalPharm is a specialist pharmaceutical company supplying proprietary branded medications and generic drugs in the area of
More informationCLINICAL POLICY Department: Medical Management Document Name: Vivitrol Reference Number: NH.PHAR.96 Effective Date: 03/12
Page: 1 of 7 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationMemantine (Ebixa) Drug treatment for Alzheimer s disease
IS 20 October 2011 Information sheet Memantine (Ebixa) Drug treatment for Alzheimer s disease Introduction... 1 How does Ebixa work?... 1 Who might benefit?... 2 What effect might Ebixa have?... 2 How
More information1. According to recent US national estimates, which of the following substances is associated
1 Chapter 36. Substance-Related, Self-Assessment Questions 1. According to recent US national estimates, which of the following substances is associated with the highest incidence of new drug initiates
More informationThese changes are prominent in individuals with severe disorders, but also occur at the mild or moderate level.
Substance-Related Disorders DSM-V Many people use words like alcoholism, drug dependence and addiction as general descriptive terms without a clear understanding of their meaning. What does it really mean
More informationBuprenorphine: what is it & why use it?
Buprenorphine: what is it & why use it? Dr Nicholas Lintzeris, MBBS, PhD, FAChAM Locum Consultant, Oaks Resource Centre, SLAM National Addiction Centre, Institute of Psychiatry Overview of presentation
More informationCare Management Council submission date: August 2013. Contact Information
Clinical Practice Approval Form Clinical Practice Title: Acute use of Buprenorphine for the Treatment of Opioid Dependence and Detoxification Type of Review: New Clinical Practice Revisions of Existing
More informationMedications for Alcohol and Drug Dependence Treatment
Medications for Alcohol and Drug Dependence Treatment Robert P. Schwartz, M.D. Medical Director Rschwartz@friendsresearch.org Friends Research Institute Medications for Alcohol Dependence Treatment Disulfiram
More informationCOMMUNITY BUPRENORPHINE PRESCRIBING IN OPIATE DEPENDENCE
COMMUNITY BUPRENORPHINE PRESCRIBING IN OPIATE DEPENDENCE INTRODUCTION High dose sublingual buprenorphine (Subutex) tablets are available in the following strengths 0.4 mg, 2 mg, and 8 mg. Suboxone tablets,
More informationPain and problem drug use
Pain and problem drug use Information for patients Prepared by the British Pain Society in consultation with the Royal College of Psychiatrists, the Royal College of General Practitioners and the Advisory
More informationa five-day medically supervised residential detoxification programme
Substance PICU and Acute Misuse and Services Detox Services Psychiatric Cygnet Hospital Intensive Harrogate Care and Acute services a five-day medically supervised residential detoxification programme
More informationSupport to Primary Care from Derbyshire Substance Misuse Service for prescribed / OTC drug dependence
Support to Primary Care from Derbyshire Substance Misuse Service for prescribed / OTC drug dependence SUMMARY 1) Derbyshire Substance misuse service provides Psycho-social treatment interventions for ALL
More informationTreatment of opioid use disorders
Treatment of opioid use disorders Gerardo Gonzalez, MD Associate Professor of Psychiatry Director, Division of Addiction Psychiatry Disclosures I have no financial conflicts to disclose I will review evidence
More informationAssessment and Management of Opioid, Benzodiazepine, and Sedative-Hypnotic Withdrawal
Assessment and Management of Opioid, Benzodiazepine, and Sedative-Hypnotic Withdrawal Roger Cicala, M. D. Assistant Medical Director Tennessee Physician s Wellness Program Step 1 Don t 1 It is legal in
More informationUpdate on Buprenorphine: Induction and Ongoing Care
Update on Buprenorphine: Induction and Ongoing Care Elizabeth F. Howell, M.D., DFAPA, FASAM Department of Psychiatry, University of Utah School of Medicine North Carolina Addiction Medicine Conference
More informationBerkshire West CCGs Alcohol Treatment Pathway for Nalmefene (Selincro) Primary Care Guidance
Berkshire West CCGs Alcohol Treatment Pathway for Nalmefene (Selincro) Primary Care Guidance Nalmefene (trade name Selincro) was given approval by NICE in November 2014 and should be available to use with
More informationPatient Information and Consent to Treatment with Buprenorphine
1063 Lower Main St, Ste C212 JEFFREY H. CHESTER, DO Phone 808.249.8887-6006 www.ponohealthcare.com Board Certified by American Board of Physical Medicine & Rehabilitation Board Certified by American Society
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) SHARED CARE AGREEMENT FRAMEWORK
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) SHARED CARE AGREEMENT FRAMEWORK ACAMPROSATE CALCIUM (Campral EC) for alcohol abstinence ESCA: Adjunct in the treatment of chronic alcohol dependence (under
More informationMEDICATIONS USED IN THE MANAGEMENT OF SUBSTANCE USE DISORDERS
MEDIATIONS USED IN THE MANAGEMENT OF SUBSTANE USE DISORDERS Opioid Agonist Therapy (OAT) for Opioid Dependence Methadone (Dolophine, Methadose) Specialty consultation advised. Titrate carefully, consider
More informationKENTUCKY ADMINISTRATIVE REGULATIONS TITLE 201. GENERAL GOVERNMENT CABINET CHAPTER 9. BOARD OF MEDICAL LICENSURE
KENTUCKY ADMINISTRATIVE REGULATIONS TITLE 201. GENERAL GOVERNMENT CABINET CHAPTER 9. BOARD OF MEDICAL LICENSURE 201 KAR 9:260. Professional standards for prescribing and dispensing controlled substances.
More informationCOUNTY OF LOS ANGELES - DEPARTMENT OF MENTAL HEALTH OFFICE OF THE MEDICAL DIRECTOR. 3.4 PARAMETERS FOR THE USE OF ANXIOLYTIC MEDICATIONS October 2014
COUNTY OF LOS ANGELES - DEPARTMENT OF MENTAL HEALTH OFFICE OF THE MEDICAL DIRECTOR 3.4 PARAMETERS FOR THE USE OF ANXIOLYTIC MEDICATIONS October 2014 I. GENERAL CONSIDERATIONS A. Definition: Anxiolytic
More informationSubstance Use Learning Event Nov 3, 2015 Bill Bullock MD, CCFP
Substance Use Learning Event Nov 3, 2015 Bill Bullock MD, CCFP Medical assessment of patient with Alcohol Use Disorder Identification patients suitable for home detox Process for referral to inpatient
More informationDrugFacts: Treatment Approaches for Drug Addiction
DrugFacts: Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please
More informationHealth Care Service System in Thailand for Patients with Alcohol Use Disorder
Health Care Service System in Thailand for Patients with Alcohol Use Disorder Health Care Service System In Thailand Screening for alcohol use disorder and withdrawal syndrome AUDIT MAST CAGE CIWA or AWS
More informationInterventions for harmful drinking and alcohol dependence
Interventions for harmful drinking and alcohol dependence A NICE pathway brings together all NICE guidance, quality standards and materials to support implementation on a specific topic area. The pathways
More informationDetox Day. RCGP June 13 th 2006. Daphne Rumball Addictions Psychiatrist. Norfolk. Daphne Rumball RCGP Detox Day June 2006 1
Detox Day RCGP June 13 th 2006 Daphne Rumball Addictions Psychiatrist Norfolk Daphne Rumball RCGP Detox Day June 2006 1 Scope of presentation Undertaking detox in the community A review of evidence and
More informationAlcohol. Problems with drinking alcohol
Alcohol Alcoholism is a word which many people use to mean alcohol dependence (alcohol addiction). Some people are problem drinkers without being dependent on alcohol. If you are alcohol- dependent then
More informationWhat you should know about treating your pain with opioids. Important information on the safe use of opioid pain medicine.
What you should know about treating your pain with opioids Important information on the safe use of opioid pain medicine. If your healthcare provider has determined that opioid therapy is right for you,
More informationUpdate and Review of Medication Assisted Treatments
Update and Review of Medication Assisted Treatments for Opiate and Alcohol Use Disorders Richard N. Whitney, MD Medical Director Addiction Services Shepherd Hill Newark, Ohio Medication Assisted Treatment
More informationShare the important information in this Medication Guide with members of your household.
MEDICATION GUIDE BUPRENORPHINE (BUE-pre-NOR-feen) Sublingual Tablets, CIII IMPORTANT: Keep buprenorphine sublingual tablets in a secure place away from children. Accidental use by a child is a medical
More informationPROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain
P a g e 1 PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain Clinical Phase 4 Study Centers Study Period 25 U.S. sites identified and reviewed by the Steering Committee and Contract
More informationMedication Assisted Treatment for Alcohol Use Disorders
Medication Assisted Treatment for Alcohol Use Disorders Jennie Wei, MD, MPH American College of Physicians New Mexico Chapter Scientific Meeting November 7, 2015 Objectives Define Alcohol Use Disorders
More informationThe CCB Science 2 Service Distance Learning Program
S2S 2055 DETOXIFICATION Module 1 Post-Test 1. A common use of a biochemical marker is. a. to support or refute other information that leads to proper diagnosis b. for forensic purposes c. in detecting
More informationAssisted alcohol withdrawal
A NICE pathway brings together all NICE guidance, quality standards and materials to support implementation on a specific topic area. The pathways are interactive and designed to be used online. This pdf
More informationINTOXICATED PATIENTS AND DETOXIFICATION
VAMC Detoxification Decision Tree Updated May 2006 INTOXICATED PATIENTS AND DETOXIFICATION Patients often present for evaluation of substance use and possible detoxification. There are certain decisions
More informationAdvanced Treatment for Opioid & Alcohol Dependence. John Larson, M.D. Corporate Medical Director Gateway Foundation
Advanced Treatment for Opioid & Alcohol Dependence John Larson, M.D. Corporate Medical Director Gateway Foundation Background 41 years practicing psychiatry Last 15 in addiction medicine I ve watched a
More informationMEDICATION GUIDE WELLBUTRIN (WELL byu-trin) (bupropion hydrochloride) Tablets
MEDICATION GUIDE WELLBUTRIN (WELL byu-trin) (bupropion hydrochloride) Tablets Read this Medication Guide carefully before you start using WELLBUTRIN and each time you get a refill. There may be new information.
More informationConsiderations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT
Considerations in Medication Assisted Treatment of Opiate Dependence Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT Disclosures Speaker Panels- None Grant recipient - SAMHSA
More informationTreatments for drug misuse
Understanding NICE guidance Information for people who use NHS services Treatments for drug misuse NICE clinical guidelines advise the NHS on caring for people with specific conditions or diseases and
More informationMinimum Insurance Benefits for Patients with Opioid Use Disorder The Opioid Use Disorder Epidemic: The Evidence for Opioid Treatment:
Minimum Insurance Benefits for Patients with Opioid Use Disorder By David Kan, MD and Tauheed Zaman, MD Adopted by the California Society of Addiction Medicine Committee on Opioids and the California Society
More informationIt is important that you tell your family and the people closest to you of this increased sensitivity to opioids and the risk of overdose.
MEDICATION GUIDE VIVITROL (viv-i-trol) (naltrexone for extended-release injectable suspension) Read this Medication Guide before you start receiving VIVITROL injections and each time you receive an injection.
More informationBuprenorphine/Naloxone Maintenance Treatment for Opioid Dependence
Buprenorphine/Naloxone Maintenance Treatment for Opioid Dependence Information for Family Members Family members of patients who have been prescribed buprenorphine/naloxone for treatment of opioid addiction
More information